, blood cultures from unique patients in the emergency department or medical intensive care units at Barnes-Jewish Hospital signaling positive and Gram-stain positive for GNB or yeast were eligible for inclusion. Standard-of-care (SOC) diagnostics were conducted in parallel with AXDX, though AXDX could be delayed up to 8 hours depending on research technician availability. Differences in time to ID and AST between SOC and AXDX were determined. Clinical outcomes included appropriateness of initial empiric antimicrobial therapy, potential for early antimicrobial de-escalation with AXDX, and mortality.
Background. Gram-negative bacteremia (GNB) is associated with significant morbidity and mortality, emphasizing the need for timely, effective antimicrobial therapy. In comparison to conventional diagnostic methods, Verigene® Blood-Culture Gram-Negative (VBC-GN) is a microarray rapid diagnostic test that identifies eight target GN organisms and six genetic resistance determinants. This study examined the potential clinical impact of VBC-GN coupled with a proposed antimicrobial stewardship (AMS)-derived treatment algorithm to guide timely, appropriate antimicrobial therapy in GNB.
Methods. Retrospective, single-center, study of adult patients (≥ 18 years) with GNB at University of Maryland Medical Center (UMMC) from September 2015 -May 2016. Patient clinical characteristics, co-morbidities, and antimicrobials administered were collected. Appropriateness of antimicrobial therapy was by in vitro susceptibility. Appropriateness of actual empiric antimicrobials received as standard care were compared with theoretical antimicrobials as guided by the UMMC AMS treatment algorithm. Two investigators (KCC and ELH) independently evaluated appropriateness of empiric and algorithm antimicrobial recommendations.
Results. 188 patients (median age 57.0 (IQR 46.5 -65.0) years) with GNB were included and 143 (76.1%) were positive for target GN organisms. Eight (4.3%) cases were GN polymicrobial, 8 (4.3%) were CTX-M positive. E. coli was the most common target GN organism (30.3%), and genitourinary was the most common source (29.3%). There was a good level of agreement between reviewers regarding appropriateness of empiric therapy (Kappa = 0.735) and algorithm recommendations (Kappa = 0.855). Overall, the proposed algorithm would have resulted in 88.4% of cases receiving appropriate antimicrobial therapy vs 78.1% actual empiric antimicrobials (P = 0.014). The AMS treatment algorithm would have resulted in 14.4% appropriate de-escalation, 4.8% inappropriate de-escalation, 5.3% appropriate escalation, and 16.0% unnecessary escalation.
Conclusion. Proposed antibiotics by AMS-derived treatment algorithm applied in conjunction with rapid diagnostic testing would result in a significantly higher proportion of patients receiving appropriate antimicrobial therapy vs. standard care. Background. Rapid diagnostics for blood cultures have shown to decrease unnecessary antibiotics; however, this has mostly been studied in gram-positive organisms. The Verigene Gram-Negative Blood Culture Test (BC-GN) identifies eight bacteria at species/genus level and six resistance genes, detected 2 hours from a positive blood culture. By identifying the gram-negative (GN) pathogen earlier compared with traditional methodology, there is the potential to decrease broad spectrum antibiotic utilization. The purpose of this study was to determine the impact of Verigene BC-GN with antibiotic stewardship on anti-pseudomonal (AP) antibiotic consumption in GN bacteremia among pathogens when AP therapy is not needed. Based on local susceptibility data, this included Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, and Proteus spp.
Methods. This multi-center, pre-post quasi-experimental study was conducted at the five hospitals that compose Scripps Healthcare. Verigene BC-GN results were communicated to pharmacists in real-time, who then notified physicians for antibiotic evaluation. Education was provided to pharmacists and physicians regarding implementation, and antibiotic selection recommendations were chosen based on site specific antibiogram data. A retrospective chart review was performed one year prior and five months post-implementation of Verigene BC-GN. Patients > 18 years old with bacteremia caused by E. coli, K. pneumoniae, K. oxytoca, or Proteus spp. within 48 hours of admission were included. The primary endpoint was AP vs. non-AP antibiotic days of therapy per day admitted (DOT/DA), within the first five days of admission. Secondary endpoints included hospital and ICU length of stay (LOS) and mortality.
Results. AP antibiotic consumption significantly decreased after implementation of Verigene BC-GN (0.45 vs. 0.32 DOT/DA, P < 0.001) while non-AP antibiotic consumption significantly increased (0.61 vs. 0.75 DOT/DA, P < 0.0001). Overall LOS was 7.0 vs. 6.2 days (P = 0.12) and in-house mortality was 7.0% and 4.3% (P = 0.18) pre and post-implementation, respectively.
Conclusion. Verigene BC-GN, with antibiotic stewardship, successfully demonstrated a shift in antibiotic utilization away from broad-spectrum AP antibiotics, in infections where Pseudomonas coverage is not necessary.
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